Genome-wide association study of Alzheimer's disease brain imaging biomarkers and neuropsychological phenotypes in the EMIF-AD Multimodal Biomarker Discovery dataset

- Jan Homann^{1§}, Tim Osburg^{1§}, Olena Ohlei¹, Valerija Dobricic¹, Laura Deecke¹, Isabelle Bos^{2,3}, 1
- Rik Vandenberghe^{4,5}, Silvy Gabel⁴, Philip Scheltens³, Charlotte E. Teunissen⁶, Sebastiaan 2
- Engelborghs^{7,8}, Giovanni Frisoni^{9,10}, Olivier Blin¹¹, Jill C. Richardson¹², Regis Bordet¹³, Alberto Lleó¹⁴, Daniel Alcolea¹⁴, Julius Popp^{15,16}, Christopher Clark¹⁵, Gwendoline Peyratout¹⁶, Pablo 3
- 4
- Martinez-Lage¹⁷, Mikel Tainta¹⁷, Richard J. B. Dobson¹⁸, Cristina Legido-Ouiglev^{19,20}, Kristel 5
- Sleegers^{21,22}, Christine Van Broeckhoven^{21,22}, Michael Wittig²³, Andre Franke²³, Christina M. Lill¹, Kaj Blennow^{24,25}, Henrik Zetterberg^{24,25,26,27}, Simon Lovestone²⁸, Johannes Streffer^{29,30}, 6
- 7
- Mara ten Kate^{3,31}, Stephanie J. B. Vos², Frederik Barkhof^{31,32}, Pieter Jelle Visser^{2,3,33}, and Lars 8 Bertram^{1,34*}
- 9

10 **§** These authors contributed equally

- 11 ¹Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck,
- 12 Germany
- ²Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, 13
- Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands 14
- ³Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Centers, 15
- Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands 16
- 17 ⁴Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
- 18 ⁵Neurology Service, University Hospital Leuven, Leuven, Belgium
- ⁶Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, 19
- Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands 20
- 21 ⁷Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 22 ⁸Department of Neurology and Center for Neurosciences, Universitair Ziekenhuis Brussel and Vrije
- Universiteit Brussel (VUB), Brussels, Belgium 23
- 24 ⁹University of Geneva, Geneva, Switzerland
- 25 ¹⁰IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
- 26 ¹¹AIX Marseille University, INS, Ap-hm, Marseille, France
- 27 ¹²Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK
- 28 ¹³University of Lille, Inserm, CHU Lille, Lille, France
- 29 ¹⁴Memory Unit, Neurology Department. Hospital de Sant Pau, Barcelona and Centro de
- Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain 30
- ¹⁵Department of Geriatric Psychiatry, University Hospital of Psychiatry Zurich, Zürich, Switzerland 31
- 32 ¹⁶Old Age Psychiatry, Department of Psychiatry, University Hospital of Lausanne, Lausanne,
- Switzerland 33

- 34 ¹⁷Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer
- 35 Foundation, San Sebastian, Spain
- ¹⁸Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and
- 37 Neuroscience, King's College London, London, UK
- 38 ¹⁹Steno Diabetes Center, Copenhagen, Denmark
- 39 ²⁰Institute of Pharmaceutical Sciences, King's College London, London, UK
- 40 ²¹Complex Genetics of Alzheimer's Disease Group, Center for Molecular Neurology, VIB, Antwerp,
- 41 Belgium
- 42 ²²Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 43 ²³Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
- ⁴⁴²⁴Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The
- 45 Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 46 ²⁵Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- 47 ²⁶Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen
- 48 Square, London, UK
- 49 ²⁷UK Dementia Research Institute at UCL, London, UK
- ²⁸Department of Psychiatry, University of Oxford, Oxford, UK (currently employed at Janssen-Cilag)
- ²⁹Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge,
- 52 University of Antwerp, Antwerp, Belgium
- 53 ³⁰AC Immune SA, EPFL Innovation Park, Lausanne, Switzerland
- ⁵⁴ ³¹Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers,
- 55 Amsterdam Neuroscience, Amsterdam, the Netherlands
- ³²Institutes of Neurology and Healthcare Engineering, University College London, London, UK
- ³³Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska
 Institutet, Stockholm, Sweden
- ³⁴Department of Psychology, University of Oslo, Oslo, Norway

60 * Correspondence:

- 61 Prof. Lars Bertram, Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of
- 62 Lübeck, Ratzeburger Allee 160, V50-319, 23562 Lübeck, Germany, phone: +49 451 3101 7491, e-
- 63 mail: lars.bertram@uni-luebeck.de

64 Keywords: genome-wide association study, GWAS, X chromosome, Alzheimer's disease, AD,

65 MRI, imaging, cognitive function

66 Abstract

67 Alzheimer's disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, ageing populations. AD susceptibility has an established genetic basis 68 which has been the focus of a large number of genome-wide association studies (GWAS) published 69 70 over the last decade. Most of these GWAS used dichotomized clinical diagnostic status, i.e. case vs. 71 control classification, as outcome phenotypes, without the use of biomarkers. An alternative and 72 potentially more powerful study design is afforded by using quantitative AD-related phenotypes as 73 GWAS outcome traits, an analysis paradigm that we followed in this work. Specifically, we utilized genotype and phenotype data from n=931 individuals collected under the auspices of the European 74 75 Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-76 AD MBD) study to perform a total of 19 separate GWAS analyses. As outcomes we used five 77 magnetic resonance imaging (MRI) traits and seven cognitive performance traits. For the latter, 78 longitudinal data from at least two timepoints were available in addition to cross-sectional 79 assessments at baseline. Our GWAS analyses revealed several genome-wide significant associations 80 for the neuropsychological performance measures, in particular those assayed longitudinally. Among the most noteworthy signals were associations in or near *EHBP1* (EH domain binding protein 1; on 81 82 chromosome 2p15) and CEP112 (centrosomal protein 112; 17q24.1) with delayed recall in a memory performance test. On the X chromosome, which is often excluded in other GWAS, we identified a 83 genome-wide significant signal near *IL1RAPL1* (interleukin 1 receptor accessory protein like 1; 84 Xp21.3). While polygenic score (PGS) analyses showed the expected strong associations with SNPs 85 86 highlighted in relevant previous GWAS on hippocampal volume and cognitive function, they did not 87 show noteworthy associations with recent AD risk GWAS findings. In summary, our study highlights 88 the power of using quantitative endophenotypes as outcome traits in AD-related GWAS analyses and

89 nominates several new loci not previously implicated in cognitive decline.

90

91 **1 Introduction**

92 Alzheimer's disease is the most common neurodegenerative disease in humans and the most common 93 form of dementia. In 2018, estimates were published that 50 million dementia patients exist 94 worldwide, about two-third of whom were diagnosed with AD (Patterson, 2018). Pathologically, AD 95 is characterized by the accumulation of extracellular amyloid β (A β) peptide deposits ("plaques") and 96 intracellular hyperphosphorylated tau protein aggregates ("tangles") in the brain, leading to synaptic 97 dysfunction, neuroinflammation, neuronal loss, and, ultimately, onset of cognitive decline (Sperling 98 et al, 2014; Mattsson et al., 2015). Genetically, AD is a heterogeneous disorder with both monogenic 99 and polygenic forms. The former is caused by highly penetrant but rare mutations in three genes 100 encoding the amyloid beta precursor protein (APP) and presenilins 1 and 2 (PSEN1/PSEN2), which 101 only make up a small fraction (<<5%) of all AD cases (Cacace et al., 2016). Most patients, however, 102 suffer from "polygenic AD", which is determined by the action (and interaction) of numerous 103 independent genomic variants, likely in concert with nongenetic factors, such as environmental 104 exposures (e.g., head trauma) and lifestyle choices (e.g., alcohol consumption and cigarette smoking) 105 (Bertram and Tanzi, 2020). Based on results from the currently most recent and largest genome-wide 106 association study (GWAS) performed in AD, there are now 38 independent loci showing genome-107 wide significant association with disease risk (Wightman et al., 2021). The most strongly and most 108 consistently associated AD risk gene is APOE, which encodes apolipoprotein E, a cholesterol 109 transport protein that has been implicated in numerous amyloid-specific pathways, including amyloid 110 trafficking, as well as plaque clearance (Holtzman et al., 2012). Although the heritability of

111 polygenic AD is estimated to be around 60-80% (Gatz et al., 2016), *APOE* and the other currently

112 known 37 independent risk loci explain only part of the disease's phenotypic variance (Wightman et

al., 2021). While most AD GWAS only consider clinically diagnosed "probable AD" cases and

- 114 cognitively unimpaired controls, involving a risk for mis-diagnosis of patients and inclusion of
- 115 preclinical AD cases as controls, additional information about the genetic architecture of AD and
- additional statistical power is also afforded by using "endophenotypes" related to AD, ideally
- 117 measured on a quantitative scale such as biomarker data, imaging, or neurocognitive performance
- 118 (Gottesman and Gould, 2003; MacRae and Vasan, 2011; Zhang et al., 2020).
- In our study, we expand earlier work from our group (Hong et al., 2020; Hong et al., 2021) derived
- 120 from European Medical Information Framework Alzheimer's Disease Multimodal Biomarker
- 121 Discovery (EMIF-AD MBD) sample (Bos et al., 2018). Specifically, in two previous GWAS we set
- 122 out to identify variants underlying variation in several cerebrospinal fluid (CSF) phenotypes, such as
- levels of CSF Aβ and tau protein (Hong et al., 2020), or neurofilament light (NfL) chain, chitinase-3like protein 1 (YKL-40), and neurogranin (Ng), which reflect axonal damage, astroglial activation.
- like protein 1 (YKL-40), and neurogranin (Ng), which reflect axonal damage, astroglial activation,
 and synaptic degeneration, respectively (Hong et al., 2021). However, the EMIF-AD MBD dataset
- features several other quantitative phenotypes, including cross-sectional MRI measurements and
- 127 cross sectional and longitudinal neuropsychological tests, which are used as outcome traits in the
- 128 current study. Specifically, we performed GWAS and polygenic score (PGS) analyses on seven
- neuropsychological (using both cross-sectional and longitudinal data) and five brain imaging
- 130 phenotypes (using cross-sectional data from MRI scans). In the 19 performed GWAS scans (which
- 131 also included the X chromosome), we identified a total of 13 genome-wide significant loci
- 132 highlighting several novel genes showing association with the analyzed traits. While we do not see a
- 133 noteworthy overlap in the genetic architectures underlying our "endophenotypes" and AD by
- 134 polygenic score (PGS) analysis, we did observe significant correlations in PGS constructed from
- earlier GWAS on hippocampal volume (Hibar et al., 2017) and general cognitive function (Davies et
- al., 2018) with the respective phenotypes in EMIF-AD MBD. Taken together, our novel results
- 137 pinpoint several new genetic loci potentially involved in AD-related pathophysiology.
- 138

139 2 Materials and Methods

140 **2.1 Sample description**

141 Analyses were based on the EMIF-AD MBD dataset which was collected across eleven different

- European study centers (Bos et al., 2018). In total, this dataset included 1221 (563 [46%] female;
- 143 mean age = 67.9 years, SD=8.3) individuals from three diagnostic stages: normal controls (NC),
- subjects with mild cognitive impairment (MCI) and subjects with a clinical diagnosis of AD. An
- 145 overview of the quantitative phenotypes investigated in this study is provided in Table 1. Due to
- partially missing phenotype data (in the neurocognitive domain), the effective sample sizes vary for the different CWAS englying (see Table 1). The least medical strikes review beards in each
- the different GWAS analyses (see Table 1). The local medical ethical review boards in each
 participating recruitment center had approved the study prior to commencement. Furthermore, all
- subjects had provided written informed consent at the time of inclusion in the cohort for use of data,
- subjects had provided written informed consent at the time of inclusion in the conort for use of samples and scans (Bos et al., 2018).
- 150 samples and scans (bos et al., 2018)

151 **2.2 MRI phenotypes description**

- 152 The five MRI phenotypes were collected for 862 subjects. Brain MRIs were used to assess
- 153 hippocampal volume (mm³, left and right hemisphere, and sum of both; all adjusted for intracranial

- volume), whole brain cortical thickness (in mm), and white matter lesions (WML; using the Fazekas
- 155 scale) (Ten Kate et al., 2018). The Fazekas scale categorizes WMLs into 4 categories: Level 0 (no or
- almost no lesion), level 1 (multiple punctate lesions), level 2 (early confluent WML), and level 3
- 157 (presence of large confluent WML). Details on the scanning procedures and data harmonization
- across centers can be found in Bos et al. (2018) and Ten Kate et al. (2018).

159 2.3 Neuropsychological phenotypes description

160 Cross-sectional (and follow-up) data were available for the following seven neuropsychological

- 161 domains within the EMIF-AD MBD dataset: global cognition (Mini Mental State Examination,
- 162 MMSE), attention, executive function, language, memory (immediate and delayed) and
- visuoconstruction. For each cognitive domain, a primary test was selected by Bos et al. (2018). If the
- preferred test were not available, an alternative priority test from the same cognitive domain was
 chosen. More details on the neuropsychological tests used for generating these phenotypes can be
- found in Bos et al. (2018). Raw data on these tests were normalized with the help of a z-
- 167 transformation, so that the data were comparable within a cognitive domain despite representing
- 168 partially different tests across centers. For the cross-sectional GWAS analyses, the *z*-scores derived
- from baseline data were used. The number of subjects used for each test can be found in the
- 170 Supplementary Material. For all seven neuropsychological domains, follow-up data from at least one
- additional time point were available for each individual and used to construct a longitudinal
- 172 phenotype using the following formula (which estimates the relative change in cognitive performance
- 173 per time interval [here: years]):

174
$$\frac{\text{Score}_{\text{last}} - \text{Score}_{\text{first}}}{\frac{\text{Score}_{\text{last}} + \text{Score}_{\text{first}}}{2} * interval}$$

- 175 When calculating longitudinal phenotypes, this formula was applied separately for each
- 176 neuropsychological test. Outlying scores were determined using false discovery rate (FDR) <0.05

177 estimations and were excluded from all subsequent analyses. Only the most frequently used tests per

178 cognitive domain were included in the final phenotypes. For more information, see Supplementary

179 Material. Both baseline and longitudinal phenotypes were adjusted for age at baseline.

180 **2.4 DNA extraction, genotype imputation and quality control**

181 A detailed description of the genotyping procedures, quality control (QC) and subsequent data

182 processing can be found in Hong et al. (2020) and in the Supplementary Material. Here, the same

183 genotype data were used for the GWAS analyses. Briefly, 936 DNA samples were subjected to

184 genome-wide SNP genotyping using the Infinium Global Screening Array (GSA) with Shared

- 185 Custom Content (Illumina Inc.). Imputation was then performed using Minimac3 (Das et al., 2016).
- 186 Extensive post-imputation QC resulted in 7,464,105 autosomal SNPs with a minor allele frequency
- 187 $(MAF) \ge 0.01$ in 888 individuals of European ancestry. More details can be found in the
- 188 Supplementary Material.
- 189 For the X chromosome, QC was performed separately for male and female subjects for non-
- 190 pseudoautosomal regions, using slightly different criteria compared to the autosomes (see
- 191 Supplementary Material). In contrast, pseudoautosomal regions (PAR1 and PAR2) were treated
- analogously to the autosomal SNPs. After QC, imputations were performed on the Sanger Institute
- 193 imputation server (https://imputation.sanger.ac.uk/) using the extended HRC reference panel
- 194 (McCarthy et al., 2016). After imputation, we used the same QC criteria as for the autosomal SNPs

- 195 but performed these separately for female and male data sets, except the HWE test (P<1.0E-4) which
- 196 was performed on all samples combined as recommended previously (Graffelmann and Weir, 2016)
- and implemented in PLINK2. For males, markers were coded as 0 vs. 2 (instead of 0 vs. 1), to adjust
- 198 for the missing second X chromosome (as recommended in Smith et al. [2021]).

199 2.5 GWAS and post-GWAS analyses

- 200 SNP-based association analyses were performed assuming an additive linear model (command: --
- 201 glm) using allele dosages (to account for imputation uncertainty) in PLINK2 (Purcell et al., 2007).
- 202 The covariates included in the analyses were sex, diagnostic status and the first three principal
- 203 components from a principal component analysis (PCA) to adjust for population-specific differences.
- 204 Generally, we excluded SNPs from the GWAS analyses with MAF<0.01. However, due to
- differences in the effective sample sizes across phenotypes this threshold was adapted upward (up to
- 206 0.04) to prevent inflation of test statistics owing to low frequency SNPs (see Table 1 for more
- details). Diagnostic status was coded with two dummy variables as follows: NC = (0,0), MCI = (0,1), AD = (1,1). For four longitudinal cognitive phenotypes an additional dummy variable was introduced
- 209 to code for the neuropsychological test used, in cases where two different tests were used for
- 210 generating these phenotypes. Details can be found in the Supplementary Material.
- 211 To explore associations on the X chromosome that were potentially driven by genetic sex, we
- additionally conducted the analyses separately in females and males. We then combined these two
- additional sets of results in a meta-analysis using Stouffer's method as implemented in METAL
- 214 (Willer et al., 2010). As we found no noteworthy differences in the results using Stouffer's method,
- 215 only the results from the linear regression analysis in the combined sample are shown.
- 216 The FUMA platform (http://fuma.ctglab.nl/; Watanabe et al., 2017) was used for post-GWAS
- analyses, including gene-based association analyses (via MAGMA (de Leeuw et al., 2015)) and to
- 218 annotate and visualize the GWAS results. To this end, we defined genome-wide significance at
- 219 $\alpha < 5.0E-08$ for the SNP-based analyses while genome-wide suggestive evidence was set at $\alpha < 1.0E-$
- 220 05. For the gene-based analyses, we adjusted for the number of protein-coding genes examined
- 221 (19,485) using the Bonferroni method, resulting in a threshold of $\alpha < 2.566$ E-06.
- In FUMA, both the SNP annotation and the Combined Annotation Dependent Depletion (CADD)
- score (Rentzsch et al., 2021) are provided. The main GWAS results are reported only for
- ²²⁴ "independent significant" SNPs, as defined by FUMA. These represent SNPs that are not highly
- 225 correlated with one another using a threshold of $r^2 < 0.6$ (using reference data from the 1000 Genomes 226 Project)
- Project).
- 227 Subsequently, the top SNPs, i.e., those with the smallest *P* values per respective phenotype, were
- examined in more detail using additional tools. First, the Variant Effect Predictor on Ensembl (VEP,
- http://grch37.ensembl.org/Tools/VEP; McLaren et al., 2016) was used to determine a possibly
- functional effect due to changes in the coding sequence, e.g. missense variants. Second, SNPs were
- examined using data from the RegulomeDB database (https://regulomedb.org/regulome-search;
 Boyle et al., 2012) to assess possible effects on gene expression. Third, we used data from the
- Boyle et al., 2012) to assess possible effects on gene expression. Third, we used data from the
 Genotype-Tissue Expression (GTEx, V8) project portal (https://www.gtexportal.org/home/; Lonsdale
- et al., 2013) to assess whether SNPs represent expression / splicing quantitative trait loci
- 235 (eQTLs/sQTLs). While GTEx provides data on gene expression in 54 tissues, we laid particular
- emphasis in genes expressed in brain. Lastly, we interrogated the GWAS catalogue
- 237 (https://www.ebi.ac.uk/gwas/home; Buniello et al., 2019) to assess whether any of the top SNPs were

- 238 previously reported to show association with other phenotypes by GWAS. To this end, we considered
- 239 genes and loci within a 1 Mb region (\pm 500,000 bp) around the SNP of interest. In case SNPs not
- identical to our "top SNP" were reported to show association with an AD-relevant phenotype (brain
- imaging, cognition, etc.), the LDlink platform (Machiela and Chanock, 2015) was used to determine
- 242 pairwise LD to top SNPs (https://ldlink.nci.nih.gov/?tab=ldpair). In this context we defined relevant
- LD using a threshold of $r^2 > 0.6$.

244 **2.6 Polygenic score (PGS) analysis**

- In addition to the primary GWAS analyses described above, we also calculated polygenic scores
- 246 (PGS) to estimate the extent of genetic correlation with the GWAS results for three other phenotypes.
- To this end, we used the summary statistics of a GWAS on AD risk (Jansen et al., 2019) as
- 248 comparison to both phenotypic domains (MRI and neurocognitive performance) of our study, and the
- GWAS on general cognitive function (Davies et al., 2018) as comparison to the GWAS on
- 250 neuropsychological phenotypes. Finally, the GWAS on hippocampal volume (Hibar et al., 2018)
- served as comparison to our GWAS analyses on MRI phenotypes. PGS calculations were performed
- using PRSice-2 software (Choi and O'Riley, 2019). Statistical analyses fitted general linear
- regression models with PGS as predictor adjusting for the same covariates as in the primary GWAS
- analyses: sex, diagnostic status, and PC1-3 (and type of cognitive test, where applicable). To adjust
- for multiple testing of this arm of our study, we used a conservative threshold based on Bonferroni adjustment ($\pi \leq 0E/02 = 0.05/(5*2)$ for the MDL share study, and $\pi \leq 0.05/(14*2)$ for the
- adjustment ($\alpha < 5.0E-03 = 0.05 / 5*2$ for the MRI phenotypes, and $\alpha < 1.8E-03 = 0.05 / 14*2$ for the neuropsychological phenotypes). However, given the (at least partial) correlation between
- neuropsychological phenotypes). However, given the (at least partial) correlation between
 phenotypes, we note that the true threshold is likely somewhere between 0.05 and these Bonferroni-
- 258 phenotypes, we note that the true threshold is likely somewhere between 0.05 and these Bonferroni-259 adjusted values.
- 260

261 **3 Results**

262 **3.1 GWAS on MRI phenotypes**

263 The genomic inflation factor λ ranged between 1.004 and 1.012 in all five SNP-based analyses,

- 264 indicating that the results of the MRI GWAS analyses were not affected by substantial inflation of
- the test statistics. In the actual association analyses of the five quantitative MRI phenotypes, we
- identified no genome-wide significant (P < 5.0 E 08) signals but observed 385 variants with at least
- suggestively significant (P < 1.0E-05) evidence of association (Supplementary Tables 15-19). The
- lowest *P* value was observed with SNP rs16829761 for the Fazekas phenotype (P=5.08E-08;
- 269 Supplementary Figure 31), which only fell slightly above the genome-wide significance threshold.
- According to VEP (McLaren et al., 2016), this variant is located in an intron of the genes *IQCJ*
- 271 (protein: IQ motif containing J) and *SCHIP1* (protein: schwannomin-interacting protein 1). In the
- GTEx database (Lonsdale et al., 2013), the lead-SNP identified here (rs16829761) is not listed as
- eQTL or sQTL, which may be due to the comparatively low MAF (0.01). The CADD score, i.e., the *in silico* predicted deleteriousness, of rs16829761 is also low at approximately 0.074. In addition,
- *in silico* predicted deleteriousness, of rs16829761 is also low at approximately 0.074. In addition, none of the gene-based GWAS analyses using MAGMA revealed any genome-wide significant
- signals (P < 2.566E-06) using the MRI traits analyzed. The genomic inflation factor λ ranged between
- 277 0.984 and 1.060 in these five gene-based analyses.

278 **3.2 GWAS on neuropsychological phenotypes**

- 279 Across the 14 GWAS performed on cross-sectional and longitudinal neuropsychological phenotypes
- available in EMIF-AD MBD, there were a total of 13 genome-wide significant loci, two of which
- were identified via the gene-based analyses using MAGMA (de Leeuw et al., 2015). Three of the
- 282 genome-wide significant signals were observed in the analyses of cross-sectional phenotype data and 283 ten with longitudinal outcomes. Overall, none of the sets of GWAS results in this arm of our study
- appeared to be strongly affected by inflation of the genome-wide test statistics as evidenced by
- 285 genomic inflation factors near 1 (range: 0.969-1.012 in the SNP-based analyses and 0.922-1.036 in
- the gene-based analyses). Table 2 provides a detailed summary of these genome-wide significant
- 287 loci, and Figure 1 shows multi-trait Manhattan (MH) plots of the SNP-based GWAS results for cross-
- 288 sectional (Figure 1A) and longitudinal (Figure 1B) analyses (for corresponding QQ plots: see
- Supplementary Figures 1 and 2). The following two paragraphs highlight the most interesting results
- in either the analyses of cross-sectional or longitudinal neuropsychological traits.
- 291 *Analyses of cross-sectional data*. The most interesting finding in this domain was elicited by markers
- in *EHBP1* which showed genome-wide significant evidence of association with the delayed recall
- 293 memory phenotype in the gene-based analysis (*P*=1.17E-07; Table 2; Supplementary Figure 20). The
- lead SNP (rs6705798) in this region only missed the genome-wide significance threshold by a small
- 295 margin (*P*=8.78E-08; Table 2; Figure 1A). *EHBP1* is located on chromosome 2p15 and encodes EH
- domain binding protein 1.
- 297 Analyses of longitudinal data. The strongest signal in the longitudinal analyses was elicited by a 298 locus on chromosome 6q27 (rs73045836; P=7.50E-11; Table 2; Figure 1B; Supplementary Figure 299 25) in the analysis using an immediate memory recall paradigm. This SNP is located in an intron of 300 SMOC2 coding for secreted modular calcium-binding protein 2, which, among other functions, 301 promotes extracellular matrix assembly (Gao et al., 2019). It needs to be noted that with an MAF 302 $\sim 2\%$ this SNP is rather infrequent which may increase the possibility of representing a false-positive 303 finding. Perhaps more interesting is the association signal observed near SNP rs 5943462 (MAF 304 ~0.05) and the visuoconstruction phenotype on the X chromosome (P=1.06E-09; Table 2; Figure 1B; 305 Supplementary Figure 29). This SNP is an intronic variant located in *IL1RAPL1* encoding interleukin 306 1 receptor accessory protein-like 1, which belongs to a class of molecules that regulate synapse 307 formation (Montani et al., 2019). The third highlighted signal in this domain relates to the genome-308 wide significant variant rs74381761 (MAF ~0.05) on chromosome 8p23.1 (P=1.89E-08; Table 2; 309 Figure 1B; Supplementary Figure 5) which shows association with the longitudinal MMSE 310 phenotype. The lead SNP is located in an intergenic region near TNKS (gene-based P=4.87E-04; 311 Table 2). This gene encodes the protein tankyrase, which belongs to a class of poly (ADP-ribose) 312 polymerases and is involved in various processes in the body, such as telomere length regulation, the 313 Wnt/ β -catenin signaling pathway, or glucose transport (Damale et al., 2020). The last featured signal 314 relates to the association observed near SNP rs9652864 (MAF ~0.22) on chromosome 17q24.1 315 (P=3.20E-08; Table 2; Figure 1B; Supplementary Figure 21) and the delayed recall test. This variant 316 is located in an intron of CEP112, which encodes centrosomal protein 112. Overall, there were eight 317 correlated SNPs in this locus all showing strongly association (Supplementary Table 10).
- 318 *Comparison of cross-sectional vs. longitudinal GWAS results*. After completion of the separate
- 319 GWAS on cross-sectional and longitudinal outcomes, we assessed whether the results of these two
- 320 analysis arms showed any overlap. To this end, we followed two approaches: First, we performed a
- 321 look-up of top results from one paradigm in the equivalent other. Specifically, we checked whether a
- 322 genome-wide significant SNP from the cross-sectional analyses also had a low *P* value in the
- 323 corresponding longitudinal GWAS and vice versa. The lowest corresponding P value was 0.015 (at
- baseline) for rs73045828, which attained P=5.65E-09 in the longitudinal GWAS for immediate

- 325 memory (Supplementary Table 21). No further signal overlaps were observed across corresponding
- 326 cross-sectional and longitudinal phenotypes. Second, we took a more comprehensive approach by
- 327 comparing a larger set of SNPs across both phenotypic domains. To this end, we constructed PGS
- from the summary statistics of the cross-sectional GWAS (as an approximate measure of "aggregated
- 329 SNP effects") and used these PGS as independent variables in a linear model predicting longitudinal 330 outcomes. Effectively, this allowed us to determine how much phenotypic variance in the
- 331 longitudinal data can be explained by top SNPs of the matching cross-sectional GWAS. Overall,
- 332 these analyses did not reveal a substantial correlation in genetic results for corresponding phenotypes
- (Supplementary Table 22), in agreement with the look up of individual SNPs (see above). The best
- 334 model fit was observed with the PGS for executive function and visuoconstruction, where the GWAS
- top SNPs from the cross-sectional data used in the PGS explained 4-9% of the phenotypic variance of
- the corresponding longitudinal outcomes, respectively (Supplementary Table 22). We note, however,
- that the PGS method was not designed for computing genetic correlations of non-independent
- 338 samples (as is the case here), so this analysis must be considered "exploratory", and the reported
- results represent no more than "upper bounds" of the potential genetic correlations.

340 **3.3 Role** *APOE* in GWAS on MRI and neuropsychological performance

341 Given the substantial role that variants in *APOE* play in the genetic architecture of AD, we present

- 342 findings for this locus separately, i.e. the results for SNP rs429358 (which defines the ε4 allele) and
- 343 rs7412 (which defines the ϵ 2 allele). In relation to the common genotype ϵ 3/ ϵ 3, the risk to develop
- AD is increased by a factor of ~3.2 for genotype $\varepsilon 3/\varepsilon 4$, while two $\varepsilon 4$ alleles (genotype $\varepsilon 4/\varepsilon 4$) show
- ORs around 10-12 when compared to normal controls (Neu et al., 2017). The minor allele at
- rs429358 ($\epsilon4$) is overrepresented in the EMIF-AD MBD dataset with an MAF ~29% (the MAF in the
- 347 general Northern European population is ~16%), which is due to the special design of participant
- recruitment (see Bos et al. (2018)). For the neuropsychological phenotypes, the *P* values of rs429358 are unremarkable except for the domain "delayed memory", where *P* values of 0.0005 and 0.0042
- were observed for the baseline and longitudinal analyses, respectively (Supplementary Table 20). In
- the MRI analyses, the only association signal observed with rs429358 was with hippocampal volume
- 352 (Supplementary Table 20). Interestingly, this was driven by an association with the volume of the left
- (P=0.0002) hippocampus, while no association was observed with the corresponding data of the right
- hemisphere (P=0.2956). We note that for both traits, i.e. delayed memory and left hippocampal
- volume, the effect direction the corresponding β coefficient is consistent with the deleterious effect of
- 356 the minor $(T/\epsilon 4)$ allele at rs429358 known from the literature (Neu et al., 2017). For the minor allele
- at rs7412 (ϵ 2) we observed no noteworthy association signals in any of the analyses performed in this
- study (Supplementary Table 20), although power for this variant was much reduced owing to its $\Delta F (4.6\% \text{ here } 7.5\% \text{ in the sense of sense of the sense o$
- lower MAF (4.6% here, 7.5% in the general western European control population).

360 **3.4 Polygenic score (PGS) analyses using published GWAS results**

- 361 In these analyses we aimed to estimate the degree of genetic overlap between the MRI and
- 362 neuropsychological outcomes available in EMIF-AD MBD and other relevant traits from the
- 363 literature, such as AD risk, using published GWAS summary statistics.
- 364 *PGS analyses with MRI phenotypes*. As expected, the strongest overlap was observed with a prior
- 365 GWAS also using MRI outcomes. Specifically, we used GWAS results by the ENIGMA group
- 366 (Hibar et al., 2017) who studied 26 imaging traits in n=33,536 individuals. Here, the best overlap was
- seen with each of the three hippocampal MRI traits (up to 2.7% variance explained, *P*=6.0E-06;
- Table 3; Supplementary Table 24). In contrast, in PGS analyses using SNPs associated with AD risk

- 369 (Jansen et al., 2019), we found only one moderate correlation with white matter damage (measured
- by the Fazekas score). For this trait the AD SNPs explained 1.4% variance (P=3.7E-03; Table 3;
- 371 Supplementary Table 24).
- 372 *PGS analyses with neuropsychological phenotypes*. As for the MRI data, the best fit in the PGS
- analyses with the neuropsychological phenotypes was observed with a GWAS that also used
- neurocognitive performance as outcome (Davies et al., 2018). Specifically, this study defined a PCA-
- derived factor for "general cognitive function" which was analyzed in >300,000 individuals. In
- EMIF-AD MBD, associations with four of the 14 calculated PGS fell below the multiple testing
- threshold of 1.8E-03 (Table 3). The strongest association was observed with the longitudinal
- attention function for which the GWAS results from Davies et al. (2018) explained 2.3% of the
- phenotypic variance (P=1.79E-03, Table 3; Supplementary Table 23). The next best associations were seen with longitudinal executive functioning ($r^2=0.028$; P=9.79E-03; Supplementary Table 23)
- and visuoconstructional abilities ($r^2=0.058$; P=3.08E-03; Supplementary Table 23). However, these
- latter two associations do not survive multiple testing correction (Table 3). Interestingly and similar
- to the MRI-based results, we did not find strong evidence for a genetic overlap between the
- neurocognitive outcomes tested here and AD risk based on Jansen et al. (2019) (Supplementary
- 385 Table 23). This included the various phenotypes measuring components of "memory" performance,
- 386 regardless of whether or not they were ascertained cross-sectionally or longitudinally.

387

388 4 Discussion

- 389 This study extends previous GWAS analyses from our group utilizing phenotypic data from the
- 390 EMIF-AD MBD study (Hong et al., 2020; Hong et al., 2021). The overarching goal of this work was
- to decipher the genetic architecture of AD-related MRI and neuropsychological (endo)phenotypes to
- better understand AD pathophysiology. Both previous EMIF-AD MBD GWAS focused on AD
- biomarkers measured in CSF and, among other findings, identified variants in *TMEM106B* as *trans*-
- pQTLs of CSF neurofilament light (NfL) levels (Hong et al., 2021). Interestingly, the same locus was
- 395 subsequently highlighted as a novel AD risk locus in a GWAS on >1.1 million individuals
- (Wightman et al. 2021), showcasing the power of the quantitative biomarker GWAS approach that
 was also followed in this study. In the current work, we focused on biomarkers / phenotypes derived
- 397 was also followed in this study. In the current work, we focused on biomarkers / phenotypes derived 398 from brain imaging and neuropsychological testing in the same EMIF-AD MBD individuals. Overall,
- we performed 19 individual GWAS and identified a total of 13 genome-wide significant loci
- 400 highlighting several novel genes that are potentially involved in contributing to AD pathophysiology.
- 401 Our study represents one of few GWAS in the literature to also include the X chromosome, where we
- 402 identified a genome-wide significant association between markers near *IL1RAPL1* and longitudinal
- 403 visuoconstructive ability. Interestingly, neither APOE nor the other recently described AD GWAS
- 404 loci appear to have a major impact on the traits analyzed in our study. In summary, our extensive
- 405 genome-wide analyses nominate several novel loci potentially involved in neurocognitive
- 406 functioning. Some of these may prove informative to better understand the genetic forces underlying
- 407 AD and related phenotypes.
- 408 In the remainder of this section, we discuss the potential role of five loci, which we consider the most
- 409 interesting findings of our study. The strongest GWAS signal was elicited by SNP rs73045836
- 410 (P=7.50E-11; Table 2; Figure 1B; Supplementary Figure 25) showing genome-wide significant
- 411 association with the longitudinal data of the immediate recall memory phenotype. The gene
- annotated to the associated region on chromosome 6q27, *SMOC2*, encodes secreted modular
- 413 calcium-binding protein 2. SMOC2 is an extracellular matrix protein from the secreted protein, acidic

414 and rich in cysteine (SPARC) family (Gao et al., 2019) recently linked to age-dependent bone loss in

415 humans (Morkmued et al., 2020). Despite performing careful literature and database searches, we

416 could not pinpoint any obvious mechanistic connection of this locus to cognitive functioning or other

417 AD-relevant phenotypes.

418 The second strongest association signal was observed near SNP rs5943462 (MAF ~0.05) on the X

419 chromosome (*P*=1.06E-09; Table 2; Figure 1B; Supplementary Figure 29) with the longitudinal data

420 of the visuoconstruction phenotype. The SNP is located in an intron of *IL1RAPL1*. This gene encodes 421 interleukin 1 receptor accessory protein-like 1, which belongs to a class of molecules that regulate

interleukin 1 receptor accessory protein-like 1, which belongs to a class of molecules that regulate
 synapse formation. *IL1RAPL1* is mostly expressed in brain areas that are involved in memory

423 development, such as hippocampus, dentate gyrus, and entorhinal cortex, suggesting that the protein

424 may have a specialized role in physiological processes underlying memory and learning abilities

425 (Montani et al., 2019). Even small changes in the expression and function of these proteins can

426 provoke major alterations in synaptic connectivity, resulting in cognitive damage (Montani et al.,

427 2019). Moreover, *IL1RAPL1* was nominated as a candidate gene for X-linked mental retardation

428 (Raymond, 2006). Although the GWAS on longitudinal visuoconstruction included only 149

429 individuals, we believe this signal to be plausible and very interesting because of the well-established

430 role of *IL1RAPL1* on human brain function.

431

432 The third highlighted signal relates to the association between variant rs74381761 (MAF ~0.05) on

433 chromosome 8p23.1 (*P*=1.89E-08; Table 2; Figure 1B; Supplementary Figure 5) and longitudinal

434 MMSE measurements. This SNP is located in an intergenic region near *TNKS*. This gene encodes the

435 protein tankyrase, which belongs to a class of poly (ADP-ribose) polymerases and is involved in

436 various processes in the body, such as telomere regulation, Wnt/β -catenin signaling pathway or 437 glucose transport (Damale et al., 2020). According to GTEx (Lonsdale et al., 2013). *TNKS* is highl

glucose transport (Damale et al., 2020). According to GTEx (Lonsdale et al., 2013), *TNKS* is highly
expressed in brain (mostly in cerebellum). Moreover, SNPs annotated to *TNKS* were associated with

438 brain white matter hyperintensity (WMH) measurements (Armstrong et al., 2020; Sargurupremraj et

439 brain white matter hyperintensity (WMH) measurements (Armstrong et al., 2020; Sargurupremraj et 440 al., 2020; Zhao et al., 2021) and cortical surface area measurements (Grasby et al., 2020) according

to the GWAS catalog (Buniello et al., 2019). With a gene-based *P* value of 4.87E-04 and the strong

functional link to brain function, we consider the signal around *TNKS* as plausible and very

443 interesting.

444 The last highlighted finding from the longitudinal analyses relates to the genome-wide significant

445 association observed between SNP rs9652864 and the delayed recall memory phenotype (P=3.20E-

446 08; Table 2; Figure 1B; Supplementary Figure 21). This variant (MAF=0.218) attained a *P* value of

447 6.73E-04 in the GWAS of Davies (2018) on cross-sectional cognitive performance, lending

448 additional support to our finding. The SNPs is located in an intron of *CEP112* which encodes

449 centrosomal protein 112. Centrosomal proteins are known as the components of the centrosome

450 involved in centricle biogenesis, cell cycle progression, and spindle-kinetochore assembly control

451 (Mazaheri Moghaddam et al., 2021). Despite showing only low levels of expression in the central

452 nervous system (CNS) according to GTEx, SNPs in this gene have been associated with cortical

453 surface area by neuroimaging in two independent GWAS (Grasby et al., 2020; van der Meer et al.,

454 2020) according to the GWAS catalog (Buniello et al., 2019). However, none of these neuroimaging

SNPs is in relevant LD ($r^2>0.6$) to the lead variant identified here. Notwithstanding, given that

456 variants in this gene have shown genetic links to both cognitive function and structural brain

457 imaging, we consider this finding as plausible and highly interesting.

458 In the GWAS analyses of the cross-sectional neurocognitive phenotypes, we observed three genome-459 wide significant signals, of which we consider the gene-based association with *EHBP1* as the most

460 interesting finding (P=1.17E-07; Table 2; Figure 1A; Supplementary Figure 20). This protein 461 interacts with Eps15-homology domain-containing protein 1/2 (EHD1/2) that plays a central role in 462 GLUT4 transport and couples endocytic vesicles to the actin cytoskeleton (Rai et al., 2020). It is 463 highly expressed in many tissues, including the brain, according to GTEx (Lonsdale et al., 2013). 464 While there does not appear to be an obvious link between EHBP1 and brain function in the literature 465 (e.g. in the GWAS catalog [Buniello et al., 2019]), we note that this gene is located within 5kb of 466 OTX1 (orthodenticle homeobox 1; gene-based P=1.19E-05), which acts as transcription factor and 467 plays a role in brain and sensory organ development in Drosophila and vertebrates, including humans (Omodei et al., 2009). Our lead SNP in this region, i.e. rs6705798, falls just short of attaining 468 469 genome-wide significance (P=8.78E-08; Table 2; Figure 1A) and is reported to represent an eQTL of both OTX1 and EHBP1 in various human tissues according to GTEx (Lonsdale et al., 2013). 470 In addition to searching for novel genetic determinants of the neuroimaging and neurocognitive traits 471 472 analyzed in this study, we also investigated the overlap with known GWAS findings. First and 473 foremost, this relates to two commonly studied alleles in the APOE gene, which appear to only play a 474 minor role in this setting. Specifically, SNP rs429358, which defines the ɛ4 allele in APOE, does not 475 even reach genome-wide suggestive significance (P < 1.0E-05) in any of the 19 GWAS investigated 476 here. The strongest associations with this allele were seen with MRI-based hippocampus volume (left 477 volume P=0.0002, summed volume P=0.0005; Supplementary Table 20) and with the delayed recall 478 memory test (baseline P=0.0005, longitudinal P=0.0042; Supplementary Table 20). The effect 479 directions of these associations are consistent with the deleterious influence of rs429358 on AD (Neu 480 et al., 2017). These at best marginal associations are in line with the literature: In the GWAS on 481 cognitive function by Davies (2018), APOE ε 4 also only showed marginal association (P=2.2E-04), 482 while it was not reported to show any evidence of association with hippocampal volume in the 483 GWAS by Hibar (2017). These findings are different from our earlier GWAS in the EMIF-AD MBD 484 dataset, where the ɛ4 allele showed very pronounced evidence of association in CSF and imaging 485 markers related to AB42 (Hong et al., 2020). Extending the comparison to additional genetic variants 486 associated with AD risk in the GWAS by Jansen et al. (2019) did also not show any noteworthy or 487 consistent overlap with the GWAS results generated in this study. In contrast, highly significant 488 overlaps by PGS analysis were observed upon using GWAS results from Davies et al. (2018) for the 489 neuropsychological and Hibar et al. (2017) for the MRI phenotypes, which is not surprising given that very similar neuropsychological and neuroimaging traits were used as outcomes in these studies. 490 491 Collectively, the PGS results of this and previous work show that there is only very limited overlap in 492 the genetic architecture (at least when studying common SNPs) between AD on the one and 493 neuropsychological performance or structural brain imaging on the other hand. We note that this does 494 not preclude the possibility that certain molecular pathways targeted by the genes highlighted in this 495 GWAS may be shared with AD pathophysiology.

496 While our study has several noteworthy strengths (e.g. the use of highly standardized procedures in 497 generating and harmonizing both the genotype and phenotype data of our study, use of both cross-498 sectional and longitudinal neurocognitive performance data, inclusion of the X chromosome in the 499 GWAS), it may also have been negatively affected by some limitations. First and foremost, we note that the sample size used for the present analyses is comparatively small for "GWAS standards" and 500 501 was well under 1,000 in some instances (Table 1). Accordingly, the statistical power of these 502 analyses was low. This limitation is at least partially countered by the quantitative nature of nearly all 503 analyzed phenotypes: it is well established that quantitative trait association analyses are more 504 powerful than those using binary phenotypes, e.g. in a case-control setting (Bush and Moore, 2012). 505 Second, in addition to resulting in low power, small sample sizes also increase the possibility of 506 false-positive findings, especially for infrequent variants (i.e. those with an MAF <5%). In this

- 507 context we note that eight of our thirteen genome-wide significant signals were elicited by such
- 508 variants. Thus, independent replication ideally in larger datasets is needed to confirm the main
- 509 findings of our GWAS before any further-reaching conclusions can be reached. Third, we note that
- the phenotype data used as outcome traits in our GWAS analyses were collected at different
- 511 participating centers at times using different types of examinations (e.g. different tests to study the 512 same overarching neuropsychological domain). To alleviate potential bias resulting from this
- 513 inherent phenotypic heterogeneity, all clinical data were processed, quality-controlled and
- 514 harmonized (e.g. by normalizing most variables within centers) centrally by an experienced team of
- 515 researchers (see Bos et al. (2018) for more details). We emphasize that this potential heterogeneity
- 516 does not apply to the genetic data as these were generated in one laboratory experiment and
- 517 subsequently processed jointly in one analytical framework, minimizing the emergence of potential
- 518 batch effects. Last but not least, we emphasize that owing to its particular ascertainment design (Bos
- et al., 2018) the EMIF-AD MBD dataset does not (attempt to) constitute a representative sample
- 520 from the "general population". Accordingly, the results presented here cannot be generalized to the
- 521 general population. We note that the same is true for many GWAS in this and other fields, which
- 522 typically use clinic-based ascertainment which is not representative of the population as a whole.
- 523 In conclusion, our study delivers an entirely novel set of GWAS results from participants of the
- 524 EMIF-AD MBD dataset. We nominate several novel and functionally interesting genetic association
- signals with phenotypes related to neurocognitive function and structural brain imaging. Even though
- 526 independent replication is still needed, our results may prove informative to better understand the
- 527 genetic forces underlying AD and related phenotypes.

528 **Conflict of Interest**

529 HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, 530 Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red 531 Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, 532 has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the 533 534 GU Ventures Incubator Program. FB is supported by the NIHR biomedical research centre at UCLH. 535 JP received consultation honoraria from Nestle Institute of Health Sciences, Ono Pharma, OM Pharma, and Fujirebio, unrelated to the submitted work. CET has a collaboration contract with ADx 536 537 Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-538 Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, 539 PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact 540 Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & 541 Neuroinflammation, and is editor of a Neuromethods book Springer. CET also holds a speaker's 542 contract with Roche, Inc. KB has served as a consultant, at advisory boards, or at data monitoring 543 committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, 544 Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-545 founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures 546 Incubator Program, outside the work presented in this paper. SL is an employee of Janssen-Cilag. JS 547 is an employee and chief medical officer of AC Immune SA. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be 548 549 construed as a potential conflict of interest.

550 Author Contributions

- 551 JH and TO performed all the analyses and together with LB interpreted the data and wrote the
- 552 manuscript. OO performed X chromosomal analyses. VD was responsible for EMIF-AD MBD DNA
- 553 sample preparation and DNA extraction. LD contributed to the interpretation of the data and
- 554 visualization of the results. IB, SV, and PJV coordinated the collection and harmonization of
- 555 phenotypes and biosamples in EMIF-AD MBD. MW and AF supervised the genotyping experiments.
- 556 RV, SG, JS, PS, CT, SE, GF, OB, JR, RB, AL, DA, JP, CC, GP, PML, MT, RD, CLQ, KS, CVB,
- 557 CL, KB, HZ, MTK, and FB contributed to sample and phenotype data collection. JS, PJV and SL are
- 558 the lead PIs for the EMIF-AD MBD study as a whole and were in charge of designing and managing
- 559 the platform. LB designed and supervised the genomics portion of the EMIF-AD MBD project and 560
- co-wrote all drafts of the manuscript. All authors critically revised all manuscripts drafts, read and
- 561 approved the final manuscript.

562 Funding

The present study was conducted as part of the EMIF-AD MBD project, which has received support 563 564 from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement No. 565 115372, the resources of which are composed of financial contribution from the European Union's 566 Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in kind contribution. Parts of 567 this study were made possible through support from the German Research Foundation (DFG grant 568 FOR2488: Main support by subproject "INF-GDAC" BE2287/7-1 to LB) and the Cure Alzheimer's 569 Fund (to LB). RV acknowledges support by the Stichting Alzheimer Onderzoek (#13007, #11020, 570 #2017-032) and the Flemish Government (VIND IWT 135043). KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA 571 572 (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, 573 Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government 574 and the County Councils; the ALF-agreement (#ALFGBG-715986); European Union Joint Program 575 for Neurodegenerative Disorders (JPND2019-466-236); and the Alzheimer's Association 2021 576 Zenith Award (ZEN-21-848495). HZ is a Wallenberg Scholar supported by grants from the Swedish 577 Research Council (#2018-02532), the European Research Council (#681712), and Swedish State 578 Support for Clinical Research (#ALFGBG-720931). SJBV received funding from the Innovative 579 Medicines Initiative 2 Joint Undertaking under ROADMAP grant agreement No. 116020 and from 580 ZonMw during the conduct of this study. Research at VIB-UAntwerp was in part supported by the 581 University of Antwerp Research Fund and SAO-FRA 2018 0016. The Lausanne study was funded by 582 a grant from the Swiss National Research Foundation (SNF 320030 141179) to JP. Research of CET 583 is supported by the European Commission (Marie Curie International Training Network, grant 584 agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council 585 (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer 586 Netherlands, Alzheimer Association. CET is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life 587 588 Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. 589 ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds.

590 Acknowledgments

591 The authors acknowledge the assistance of Ellen De Roeck, Naomi De Roeck, and Hanne Struyfs

- 592 (UAntwerp) with data collection. We thank Mrs. Tanja Wesse and Mrs. Sanaz Sedghpour Sabet at
- 593 the Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
- 594 for technical assistance with the GSA genotyping. We thank Dr. Fabian Kilpert for his assistance
- 595 with the QC and genotype imputations and Marcel Schilling for his assistance on visualizing the

- 596 results. The LIGA team acknowledges computational support from the OMICS compute cluster at
- 597 the University of Lübeck.

598 **References**

- 599 Armstrong, N. J., Mather, K. A., Sargurupremraj, M., Knol, M. J., Malik, R., Satizabal, C. L., et al.
- 600 (2020). Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White
- 601 Matter Hyperintensities. *Stroke*, 51:7, 2111–2121. doi:10.1161/STROKEAHA.119.027544
- Bertram, L., and Tanzi, R. E. (2020). Genomic mechanisms in Alzheimer's disease. *Brain pathology* (*Zurich, Switzerland*), 30:5, 966–977. doi:10.1111/bpa.12882
- Bos, I., Vos, S., Vandenberghe, R., Scheltens, P., Engelborghs, S., Frisoni, G., et al. (2018). The
- 605 EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort
- 606 characteristics. Alzheimer's research and therapy, 10:1, 64. doi:10.1186/s13195-018-0396-5
- Boyle, A. P., Hong, E. L., Hariharan, M., Cheng, Y., Schaub, M. A., Kasowski, M., et al. (2012).
 Annotation of functional variation in personal genomes using RegulomeDB. *Genome research*, 22:9, 1790–1797. doi:10.1101/gr.137323.112
- 610
 - Buniello, A., MacArthur, J., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., et al. (2019).
 - The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic acids research*, 47:D1, D1005–D1012. doi:10.1093/nar/gky1120
 - 614

- Bush, W. S., and Moore, J. H. (2012). Chapter 11: Genome-wide association studies. *PLoS computational biology*, 8:12, e1002822. doi:10.1371/journal.pcbi.1002822
- 618 Cacace, R., Sleegers, K., and Van Broeckhoven, C. (2016). Molecular genetics of early -onset
- 619 Alzheimer's disease revisited. Alzheimer's & dementia: the journal of the Alzheimer's Association,
- 620 12:6, 733–748. doi:10.1016/j.jalz.2016.01.012
- Choi, S. W., and O'Reilly, P. F. (2019). PRSice-2: Polygenic Risk Score software for biobank-scale
 data. *GigaScience*, 8(7), giz082. doi:10.1093/gigascience/giz082
- Damale, M. G., Pathan, S. K., Shinde, D. B., Patil, R. H., Arote, R. B., and Sangshetti, J. N. (2020).
- Insights of tankyrases: A novel target for drug discovery. *European journal of medicinal chemistry*,
 207, 112712. doi:10.1016/j.ejmech.2020.112712
- 626
 - Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A., et al. (2016). Next-generation
 genotype imputation service and methods. *Nature genetics*, 48:10, 1284–1287. doi:10.1038/ng.3656
 - 629
 - Davies, G., Lam, M., Harris, S. E., Trampush, J. W., Luciano, M., Hill, W. D., et al. (2018). Study of
- 631 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.
 632 *Nature communications*, 9:1, 2098, doi:10.1038/s41467-018-04362-x
- 633 de Leeuw, C. A., Mooij, J. M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized gene-set
- 634 analysis of GWAS data. *PLoS computational biology*, 11:4, e1004219.
- 635 doi:10.1371/journal.pcbi.1004219

- 636 Gao, Q., Mok, H. P., and Zhuang, J. (2019). Secreted modular calcium-binding proteins in
- 637 pathophysiological processes and embryonic development. Chinese medical journal, 132:20, 2476-
- 2484. doi:10.1097/CM9.000000000000472 638
- 639 Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., et al. (2006).
- 640 Role of genes and environments for explaining Alzheimer disease. Archives of general psychiatry, 641
- 63:2, 168-174. doi:10.1001/archpsyc.63.2.168
- 642
- 643 Gottesman, I. I., and Gould, T. D. (2003). The endophenotype concept in psychiatry: etymology and
- 644 strategic intentions. The American journal of psychiatry, 160:4, 636-645.
- 645 doi:10.1176/appi.ajp.160.4.636
- 646
- 647 Graffelman, J., and Weir, B. S. (2016). Testing for Hardy-Weinberg equilibrium at biallelic genetic 648 markers on the X chromosome. *Heredity*, 116:6, 558–568. doi:10.1038/hdy.2016.20
- 649
- 650 Grasby, K. L., Jahanshad, N., Painter, J. N., Colodro-Conde, L., Bralten, J., Hibar, D. P., et al.
- 651 (2020). The genetic architecture of the human cerebral cortex. Science (New York, N.Y.), 367:6484, 652 eaay6690. doi:10.1126/science.aay6690
- 653 Hibar, D. P., Adams, H., Jahanshad, N., Chauhan, G., Stein, J. L., Hofer, M. A., et al. (2017). Novel
- 654 genetic loci associated with hippocampal volume. Nature communications, 8, 13624.
- 655 doi:10.1038/ncomms13624
- 656 Holtzman, D. M., Herz, J., and Bu, G. (2012). Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor perspectives in medicine, 2:3, 657 658 a006312.doi:10.1101/cshperspect.a006312
- 659 Hong, S., Prokopenko, D., Dobricic, V., Kilpert, F., Bos, I., Vos, S., et al. (2020). Genome-wide 660 association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker
- 661 Discovery dataset. Translational psychiatry, 10:1, 403. doi:10.1038/s41398-020-01074-z
- 662 Hong, S., Dobricic, V., Ohlei, O., Bos, I., Vos, S., Prokopenko, D., et al. (2021). TMEM106B and
- 663 CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker
- 664 levels. Alzheimer's and dementia: the journal of the Alzheimer's Association, 17:10, 1628–1640.
- 665 doi:10.1002/alz.12330
- 666 Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., et al. (2019). 667 Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's 668 disease risk. Nature genetics, 51:3, 404-413. doi:10.1038/s41588-018-0311-9
- 669 Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., et al. (2013). The Genotype-670 Tissue Expression (GTEx) project. Nature genetics, 45:6, 580–585. doi:10.1038/ng.2653
- 671
- 672 Machiela, M. J., and Chanock, S. J. (2015). LDlink: a web-based application for exploring
- 673 population-specific haplotype structure and linking correlated alleles of possible functional variants.
- 674 Bioinformatics (Oxford, England), 31:21, 3555–3557. doi:10.1093/bioinformatics/btv402 675
- 676 MacRae, C. A., and Vasan, R. S. (2011). Next-generation genome-wide association studies; time to
- 677 focus on phenotype?. Circulation. Cardiovascular genetics, 4:4, 334-336.
- 678 doi:10.1161/CIRCGENETICS.111.960765

679 Martin, P. M., Carnaud, M., Garcia del Caño, G., Irondelle, M., Irinopoulou, T., Girault, J. A., et al. 680 (2008). Schwannomin-interacting protein-1 isoform IQCJ-SCHIP-1 is a late component of nodes of 681 Ranvier and axon initial segments. The Journal of neuroscience : the official journal of the Society 682 for Neuroscience, 28:24, 6111–6117. doi:10.1523/JNEUROSCI.1044-08.2008 683 Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Sr, Nikolcheva, T., Pesini, P., et al. 684 (2015). Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's & 685 dementia (Amsterdam, Netherlands), 1:4, 412–419. doi:10.1016/j.dadm.2015.09.001 686 Martin, P. M., Cifuentes-Diaz, C., Devaux, J., Garcia, M., Bureau, J., Thomasseau, S., et al. (2017). 687 Schwannomin-interacting Protein 1 Isoform IQCJ-SCHIP1 Is a Multipartner Ankyrin- and Spectrin-688 binding Protein Involved in the Organization of Nodes of Ranvier. The Journal of biological 689 chemistry, 292:6, 2441-2456. doi:10.1074/jbc.M116.758029 690 691 Mazaheri Moghaddam, M., Mazaheri Moghaddam, M., Hamzeiy, H., Baghbanzadeh, A., 692 Pashazadeh, F., and Sakhinia, E. (2021). Genetic basis of acephalic spermatozoa syndrome, and 693 intracytoplasmic sperm injection outcomes in infertile men: a systematic scoping review. *Journal of* 694 assisted reproduction and genetics, 38:3, 573-586. doi:10.1007/s10815-020-02008-w 695 696 McCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A. R., Teumer, A., et al. (2016). A 697 reference panel of 64.976 haplotypes for genotype imputation. *Nature genetics*, 48:10, 1279–1283. 698 doi:10.1038/ng.3643 699 700 McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R., Thormann, A., et al. (2016). The 701 Ensembl Variant Effect Predictor. Genome biology, 17:1, 122. doi:10.1186/s13059-016-0974-4 702 Montani, C., Gritti, L., Beretta, S., Verpelli, C., and Sala, C. (2019). The Synaptic and Neuronal 703 704 Functions of the X-Linked Intellectual Disability Protein Interleukin-1 Receptor Accessory Protein 705 Like 1 (IL1RAPL1). Developmental neurobiology, 79:1, 85–95. doi:10.1002/dneu.22657 706 707 Morkmued, S., Clauss, F., Schuhbaur, B., Fraulob, V., Mathieu, E., Hemmerlé, J., et al. (2020). 708 Deficiency of the SMOC2 matricellular protein impairs bone healing and produces age-dependent 709 bone loss. Scientific reports, 10:1, 14817. doi:10.1038/s41598-020-71749-6 710 711 Neu, S. C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., et al. (2017). Apolipoprotein 712 E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA neurology, 74:10, 713 1178–1189. doi:10.1001/jamaneurol.2017.2188 714 715 Omodei, D., Acampora, D., Russo, F., De Filippi, R., Severino, V., Di Francia, R., et al. (2009). 716 Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B 717 cells and in aggressive Non-Hodgkin Lymphoma. The American journal of pathology, 175:6, 2609-718 2617. doi:10.2353/ajpath.2009.090542 719 Patterson, C. (2018) World Alzheimer Report 2018. The State of the Art of Dementia Research: New 720 Frontiers. An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer's Disease International. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., et al. (2007). 721 722 PLINK: a tool set for whole-genome association and population-based linkage analyses. American 723 journal of human genetics, 81:3, 559–575. doi:10.1086/519795

GWAS in EMIF-AD MBD dataset

- 724 Quintino-Santos, S., Diniz, B. S., Firmo, J. O., Moriguchi, E. H., Lima-Costa, M. F., and Castro-
- 725 Costa, E. (2015). APOE £4 allele is associated with worse performance in memory dimensions of the
- 726 mini-mental state examination: the Bambuí Cohort Study of Aging. *International journal of geriatric*
- 727 *psychiatry*, 30:6, 573–579. doi:10.1002/gps.4186
- 728
- Rai, A., Bleimling, N., Vetter, I. R., and Goody, R. S. (2020). The mechanism of activation of the
 actin binding protein EHBP1 by Rab8 family members. *Nature communications*, 11:1, 4187.
- 731 doi:10.1038/s41467-020-17792-3
- 732
- Raymond F. L. (2006). X linked mental retardation: a clinical guide. *Journal of medical genetics*,
 43:3, 193–200. doi:10.1136/jmg.2005.033043
- 735
- Rentzsch, P., Schubach, M., Shendure, J., and Kircher, M. (2021). CADD-Splice-improving genomewide variant effect prediction using deep learning-derived splice scores. *Genome medicine*, 13:1, 31.
 doi:10.1186/s13073-021-00835-9
- 740 Sargurupremraj, M., Suzuki, H., Jian, X., Sarnowski, C., Evans, T. E., Bis, J. C., et al. (2020).
- Cerebral small vessel disease genomics and its implications across the lifespan. *Nature communications*, 11:1, 6285. doi:10.1038/s41467-020-19111-2
- 743 Scheufele, E., Aronzon, D., Coopersmith, R., McDuffie, M. T., Kapoor, M., Uhrich, C. A., et al.
- 744 (2014). tranSMART: An Open Source Knowledge Management and High Content Data Analytics
- Platform. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on
 Translational Science, 2014, 96–101.
- Smith, S. M., Douaud, G., Chen, W., Hanayik, T., Alfaro-Almagro, F., Sharp, K., et al. (2021). An
 expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank. *Nature neuroscience*, 24:5, 737–745. doi:10.1038/s41593-021-00826-4
- Sperling, R., Mormino, E., and Johnson, K. (2014). The evolution of preclinical Alzheimer's disease:
 implications for prevention trials. *Neuron*, 84:3, 608–622. doi: 10.1016/j.neuron.2014.10.038
- 752
- 753 Ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S. J., Vandenberghe, R., et al. (2018). MRI
- predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
 Alzheimer's research & therapy, 10:1, 100. doi:10.1186/s13195-018-0428-1
- 756
- van der Meer, D., Frei, O., Kaufmann, T., Shadrin, A. A., Devor, A., Smeland, O. B., et al. (2020).
- Understanding the genetic determinants of the brain with MOSTest. *Nature communications*, 11:1,
 3512. doi:10.1038/s41467-020-17368-1
- 760 Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional mapping and
- annotation of genetic associations with FUMA. *Nature communications*, 8:1, 1826.
- 762 doi:10.1038/s41467-017-01261-5
- 763 Wightman, D. P., Jansen, I. E., Savage, J. E., Shadrin, A. A., Bahrami, S., Holland, D., et al. (2021).
- A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's
 disease. *Nature genetics*, 53:9, 1276–1282. doi:10.1038/s41588-021-00921-z

- 766 Willer, C. J., Li, Y., and Abecasis, G. R. (2010). METAL: fast and efficient meta-analysis of
- 767 genomewide association scans. Bioinformatics (Oxford, England), 26:17, 2190-2191.
- 768 doi:10.1093/bioinformatics/btg340
- 769 Zhang, O., Cai, Z., Lhomme, M., Sahana, G., Lesnik, P., Guerin, M., et al. (2020). Inclusion of
- 770 endophenotypes in a standard GWAS facilitate a detailed mechanistic understanding of genetic
- 771 elements that control blood lipid levels. Scientific reports, 10:1, 18434. doi:10.1038/s41598-020-772 75612-6
- 773

774 Zhao, B., Zhang, J., Ibrahim, J. G., Luo, T., Santelli, R. C., Li, Y., et al. (2021). Large-scale GWAS 775 reveals genetic architecture of brain white matter microstructure and genetic overlap with cognitive 776 and mental health traits (n = 17,706). *Molecular psychiatry*, 26:8, 3943–3955. doi:10.1038/s41380-

777 019-0569-z

778 **Data Availability Statement**

- 779 GWAS summary statistics for the top (P value < 1.0E-05) results are listed in the Supplementary
- 780 Tables. Full GWAS summary statistics are available from the authors upon request. Clinical data and
- 781 genome-wide genotyping data are stored on an online data platform using the "tranSMART" data
- 782 warehouse framework. Access to the genome-wide genotyping data can be requested from the
- 783 corresponding author of this study who will forward each request to the EMIF-AD data access team.
- 784 All scripts used to generate the primary GWAS and PGS analyses are available from the authors 785 upon request.

Figure legends 786

- 787 Figure 1: Multi-trait Manhattan plots for the SNP-based GWAS results on neuropsychological
- 788 phenotypes (A: cross-sectional; B: longitudinal). For details on the analyzed traits see Methods and
- 789 Supplementary Material.

790 Tables

791 **Table 1:** Description of EMID-AD MBD datasets analyzed per phenotype.

792 "MAF filter" denotes the applied MAF filter for each GWAS. For cross-sectional MMSE we used an MAF threshold of 0.02 due to residual

inflation of the GWAS test statistics. Information on tests used for generating baseline and longitudinal phenotypes can be found in the
 Supplementary Material. MMSE = Mini Mental State Examination. "n.a." = not available.

		Base	eline	Longitudinal		
Category Phenotype		Sample size	MAF filter	Sample size	MAF filter	
	MMSE	867	0.02	520	0.02	
	Attention	806	0.01	402	0.02	
Neuropsychological	Executive functioning	686	0.01	234	0.02	
	Language	849	0.01	409	0.02	
	Memory Delayed	729	0.01	337	0.02	
	Memory Immediate	797	0.01	345	0.02	
	Visuoconstruction	429	0.02	149	0.04	
	Fazekas score	606	0.01	n.a.	n.a.	
MRI	Cortical thickness	560	0.01	n.a.	n.a.	
	Left Hippocampus volume	605	0.01	n.a.	n.a.	
	Right Hippocampus volume	605	0.01	n.a.	n.a.	
	Summed Hippocampus volume	605	0.01	n.a.	n.a.	

Table 2: Genome-wide significant associations observed in GWAS of cognitive phenotypes.

797 **Bold font** indicates genome-wide significant (on SNP- or gene-level) results (see Methods section for details). "Chr" and "Position"

according to GRCh37/hg19. "A1" denotes the effect allele. "P (SNP)" is the *P* value of the lead SNP at this locus. "P (Gene)" is the *P* value

belonging to "Nearest gene". Top results from these GWAS analyses can be found in the Supplementary Tables. MMSE = Mini Mental State

800 Examination. "n.a." = not available.

Study arm	Phenotype	Lead variant	Chr	Position	Nearest gene	A1	A2	Beta	MAF	P (SNP)	P (Gene)
Cross-sectional	MemoryDelayed	rs6705798	2p15	63259881	EHBP1	С	Т	-0.32739	0.358	8.78E-08	1.17E-07
	MMSE	rs2122118	2q33.3	207252439	AC017081.2	G	А	-2.82266	0.022	3.03E-09	n.a.
	Visuoconstruction	rs113492235	4q34.2	177252900	SPCS3	Т	С	-2.17956	0.022	1.51E-08	0.15674
Longitudinal	MemoryImmediate	rs73045836	6q27	169062739	SMOC2	G	Т	-0.36094	0.020	7.50E-11	0.0035373
	MMSE	rs74381761	8p23.1	9389761	TNKS	С	G	-0.08453	0.048	1.89E-08	0.00048716
	Attention	rs116900143	10q23.31	92588290	HTR7	С	Т	-0.35173	0.023	1.95E-08	0.019663
	MemoryImmediate	rs11217863	11q23.3	120293138	AP002348.1	А	G	-0.16626	0.080	7.81E-08	8.91E-07
	Attention	rs111959303	12q14.3	66844015	GRIP1	Т	С	0.37459	0.022	2.52E-08	0.81478
	Attention	rs34736485	16q23.2	79272611	RP11-679B19.2	Т	G	0.31924	0.022	1.59E-08	n.a.
	MemoryDelayed	rs9652864	17q24.1	63741645	CEP112	А	Т	0.29184	0.218	3.20E-08	0.016339
	MemoryImmediate	rs146202660	18q21.1	45022937	CTD-2130013.1	Т	G	-0.29342	0.029	4.63E-08	n.a.
	Executive	rs16982556	20q13.32	57801889	ZNF831	Т	С	-0.29752	0.062	1.26E-08	0.0025565
	Visuoconstruction	rs5943462	Xp21.3	28823154	IL1 RAPL1	G	С	-0.14082	0.051	1.06E-09	0.006719

802 **Table 3:** Summary of PGS results significant after multiple testing correction.

803 "Threshold" refers to P value cut-off used for PGS construction in prior GWAS summary statistics and "Number of SNPs" refers to the LD-

804 pruned SNPs passing this threshold that are included in PGS calculations. "R2" denotes the phenotypic variance explained by the SNPs of

the prior GWAS in the EMIF-AD MBD dataset. A full listing of results from these PRS analyses can be found in Supplementary Material.
 MMSE = Mini Mental State Examination.

807

Prior GWAS	Phenotype	Threshold	Number of SNPs	R2	P value
	Hippocampus volume sum	0.0001	127	0.027	6.06E-06
Hibar et al. (2017)	Hippocampus volume left	0.0001	127	0.026	9.98E-06
	Hippocampus volume right	0.0001	127	0.024	2.48E-05
Jansen et al. (2019)	Fazekas	0.17075	22269	0.014	3.72E-03
Davies et al. (2018)	Baseline MMSE	0.248	63792	0.016	1.66E-06
	Baseline executive functioning	0.0014	4469	0.018	1.98E-05
	Baseline language	0.0061	9031	0.010	1.25E-03
	Longitudinal attention	5.0E-08	163	0.023	1.79E-03

